Bioliberty, a medtech company headquartered in Edinburgh and Boston, has secured $10.2 million in funding to further develop its rehabilitation technology and expand into the U.S. market.
The round includes an $8.2 million Series A led by the Scottish National Investment Bank, alongside participation from Archangels, Eos Advisory, Old College Capital, Hanna Capital, and Conduit Connect. This follows a $2 million pre-Series A raised in 2025.
Supporting Next Phase Of Commercial Growth
The new capital will be used to accelerate product development and support the rollout of Bioliberty’s Lifehub Clinic platform in the United States.
As part of the expansion, the company has also strengthened its board with healthcare industry leaders bringing experience in rehabilitation and policy.
Advertisement
Advancing Rehabilitation Through Robotics
Founded in 2020, Bioliberty develops assistive technologies designed to support recovery from mobility impairments.
Its core product, a soft robotic glove, is built to improve both hand opening and closing functions, helping patients regain strength and coordination during rehabilitation.
The system also captures detailed movement data, allowing clinicians to monitor progress and adjust treatment plans based on real-world performance.
Data-Driven Approach To Patient Recovery
By combining robotics with data analytics, the startup aims to deliver more personalised rehabilitation.
The platform tracks key indicators of upper limb mobility and provides insights that support clinical decision-making, recovery planning, and patient discharge processes.
About Bioliberty
Bioliberty develops rehabilitation technologies focused on restoring mobility and independence. Its solutions combine soft robotics with data-driven insights to support patients recovering from injury or neurological conditions while enabling more effective therapy and clinical outcomes.
